Merck: signs collaboration with Exelixis

(CercleFinance.com) - Exelixis and Merck sign a clinical development collaboration to evaluate investigational zanzalintinib in combination with KEYTRUDA (pembrolizumab) in head and neck cancer, and in combination with WELIREG (belzutifan), in renal cell carcinoma.


Under the terms of this collaboration, Merck will supply KEYTRUDA for the ongoing STELLAR-305 pivotal Phase 3 trial, sponsored by Exelixis, in previously untreated recurrent or metastatic HNSCC-L1 positive patients.

In addition, Merck will sponsor one phase 1/2 and two phase 3 pivotal trials in RCC. Merck will fund one of these Phase 3 studies, and Exelixis will co-fund the Phase 1/2 trial and the other Phase 3 study, as well as zanzalintinib and cabozantinib. Exelixis retains all worldwide commercial and marketing rights to zanzalintinib.

Merck remains committed to building on progress to date by strategically evaluating the potential of new combination regimens to improve outcomes for more patients, Merck said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.